XBIT vs. XERS, PBYI, VSTM, ME, TSVT, NKTR, PYXS, ACIU, ALDX, and CDT
Should you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Xeris Biopharma (XERS), Puma Biotechnology (PBYI), Verastem (VSTM), 23andMe (ME), 2seventy bio (TSVT), Nektar Therapeutics (NKTR), Pyxis Oncology (PYXS), AC Immune (ACIU), Aldeyra Therapeutics (ALDX), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
XBiotech received 178 more outperform votes than Xeris Biopharma when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 69.50% of users gave Xeris Biopharma an outperform vote.
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 28.4% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Xeris Biopharma has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
XBiotech has a net margin of 0.00% compared to XBiotech's net margin of -37.98%. Xeris Biopharma's return on equity of -10.82% beat XBiotech's return on equity.
In the previous week, XBiotech had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 2 mentions for XBiotech and 0 mentions for Xeris Biopharma. XBiotech's average media sentiment score of 0.00 equaled Xeris Biopharma'saverage media sentiment score.
Xeris Biopharma currently has a consensus price target of $4.88, suggesting a potential upside of 174.65%. Given XBiotech's higher possible upside, equities research analysts clearly believe Xeris Biopharma is more favorable than XBiotech.
XBiotech has lower revenue, but higher earnings than Xeris Biopharma. XBiotech is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
XBiotech beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks.
Get XBiotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XBiotech Competitors List
Related Companies and Tools
